Kiadis Pharma rais­es €31.2 mil­lion in a pri­vate place­ment of 3.9 mil­lion new shares

Amsterdam, The Netherlands, October 19, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny, today announces that it has raised gross pro­ceeds of €31.2 mil­lion through a pri­vate place­ment of 3.9 mil­lion new shares to insti­tu­tion­al investors via an accel­er­at­ed book­build­ing process as announced on October 18, 2018 (the “Placing”). The Placing was com­plet­ed at a sub­scrip­tion price of €8.00 per share and rep­re­sent­ed approx­i­mate­ly 19% of the issued share cap­i­tal of the Company pri­or to the trans­ac­tion. The new ordi­nary shares will rank pari pas­su in all respects with the cur­rent­ly out­stand­ing shares of the Company and are expect­ed to be list­ed and trad­ed on Euronext Amsterdam and Euronext Brussels on October 23, 2018. Following the Placing, the issued share cap­i­tal of the Company will con­sist of 24,341,410 ordi­nary shares.

Arthur Lahr, CEO of Kiadis Pharma, com­ment­ed: “Today’s over­sub­scribed pri­vate place­ment shows investors’ com­mit­ment and trust in Kiadis Pharma’s progress and poten­tial. I’m delight­ed to wel­come sev­er­al new glob­al spe­cial­ist health­care investors to our share reg­is­ter. With the €31.2 mil­lion raised in this offer­ing and if we draw the exist­ing €15m debt facil­i­ty upon a pos­i­tive CHMP opin­ion, we would have suf­fi­cient funds into the sec­ond half of 2020.

Kiadis Pharma intends to use the net pro­ceeds of the Placing to:
– Continue the Phase 3 inter­na­tion­al, ran­dom­ized, con­trolled, mul­ti-cen­tre clin­i­cal tri­al for ATIR101 in the United States, Canada and Europe;
– Further pre­pare for com­mer­cial­iza­tion in Europe by invest­ing into mar­ket access prepa­ra­tion, reim­burse­ment, com­mer­cial orga­ni­za­tion and com­mer­cial man­u­fac­tur­ing;
– Apply funds for gen­er­al cor­po­rate pur­pos­es and oth­er work­ing cap­i­tal needs.

Jefferies International Limited (“Jefferies”) act­ed as Global Coordinator. Jefferies and Kempen & Co N.V. act­ed as Joint Bookrunners and KBC Securities N.V. and Oppenheimer & Co. Inc. act­ed as Co-Managers in con­nec­tion with the Placing. Saola Healthcare Partners act­ed as finan­cial advi­sor to the Company.